Literature DB >> 19305151

PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches.

Giovanni Ligresti1, Loredana Militello, Linda S Steelman, Andrea Cavallaro, Francesco Basile, Ferdinando Nicoletti, Franca Stivala, James A McCubrey, Massimo Libra.   

Abstract

Phosphatidylinositol 3-kinases (PI3Ks) are a group of lipid kinases that regulate signaling pathways involved in cell proliferation, adhesion, survival and motility. The PI3K pathway is considered to play an important role in tumorigenesis. Activating mutations of the p110alpha subunit of PI3K (PIK3CA) have been identified in a broad spectrum of tumors. Analyses of PIK3CA mutations reveals that they increase the PI3K signal, stimulate downstream Akt signaling, promote growth factor-independent growth and increase cell invasion and metastasis. In this review, we analyze the contribution of the PIK3CA mutations in cancer, and their possible implications for diagnosis and therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19305151      PMCID: PMC3781181          DOI: 10.4161/cc.8.9.8255

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  40 in total

Review 1.  Signaling by distinct classes of phosphoinositide 3-kinases.

Authors:  B Vanhaesebroeck; M D Waterfield
Journal:  Exp Cell Res       Date:  1999-11-25       Impact factor: 3.905

2.  A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Authors:  Katrien Berns; Hugo M Horlings; Bryan T Hennessy; Mandy Madiredjo; E Marielle Hijmans; Karin Beelen; Sabine C Linn; Ana Maria Gonzalez-Angulo; Katherine Stemke-Hale; Michael Hauptmann; Roderick L Beijersbergen; Gordon B Mills; Marc J van de Vijver; René Bernards
Journal:  Cancer Cell       Date:  2007-10       Impact factor: 31.743

Review 3.  PTEN: life as a tumor suppressor.

Authors:  L Simpson; R Parsons
Journal:  Exp Cell Res       Date:  2001-03-10       Impact factor: 3.905

4.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Authors:  Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

Review 5.  Ribosomal S6 kinase signaling and the control of translation.

Authors:  A Dufner; G Thomas
Journal:  Exp Cell Res       Date:  1999-11-25       Impact factor: 3.905

6.  Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis.

Authors:  C Page; H J Lin; Y Jin; V P Castle; G Nunez; M Huang; J Lin
Journal:  Anticancer Res       Date:  2000 Jan-Feb       Impact factor: 2.480

7.  PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas.

Authors:  Frank Schönleben; Wanglong Qiu; Helen E Remotti; Werner Hohenberger; Gloria H Su
Journal:  Langenbecks Arch Surg       Date:  2008-02-21       Impact factor: 3.445

8.  The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations.

Authors:  Chuan-Hsiang Huang; Diana Mandelker; Oleg Schmidt-Kittler; Yardena Samuels; Victor E Velculescu; Kenneth W Kinzler; Bert Vogelstein; Sandra B Gabelli; L Mario Amzel
Journal:  Science       Date:  2007-12-14       Impact factor: 47.728

9.  A role of the kinase mTOR in cellular transformation induced by the oncoproteins P3k and Akt.

Authors:  M Aoki; E Blazek; P K Vogt
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-02       Impact factor: 11.205

10.  PIK3CA-activating mutations and chemotherapy sensitivity in stage II-III breast cancer.

Authors:  Cornelia Liedtke; Luca Cardone; Attila Tordai; Kai Yan; Henry L Gomez; Luis J Barajas Figureoa; Rebekah E Hubbard; Vicente Valero; Eduardo A Souchon; W Fraser Symmans; Gabriel N Hortobagyi; Alberto Bardelli; Lajos Pusztai
Journal:  Breast Cancer Res       Date:  2008-03-27       Impact factor: 6.466

View more
  72 in total

1.  Oncogene mutation profiling of pediatric solid tumors reveals significant subsets of embryonal rhabdomyosarcoma and neuroblastoma with mutated genes in growth signaling pathways.

Authors:  Neerav Shukla; Nabahet Ameur; Ismail Yilmaz; Khedoudja Nafa; Chyau-Yueh Lau; Angela Marchetti; Laetitia Borsu; Frederic G Barr; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2011-12-05       Impact factor: 12.531

Review 2.  Drugging the PI3 kinome: from chemical tools to drugs in the clinic.

Authors:  Paul Workman; Paul A Clarke; Florence I Raynaud; Rob L M van Montfort
Journal:  Cancer Res       Date:  2010-02-23       Impact factor: 12.701

3.  Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors.

Authors:  Monica Mita; Siqing Fu; Sarina Anne Piha-Paul; Filip Janku; Alain Mita; Ronald Natale; Wei Guo; Charles Zhao; Razelle Kurzrock; Aung Naing
Journal:  Invest New Drugs       Date:  2017-02-13       Impact factor: 3.850

Review 4.  Targeting signal transduction pathways to eliminate chemotherapeutic drug resistance and cancer stem cells.

Authors:  James A McCubrey; Stephen L Abrams; Kristin Stadelman; William H Chappell; Michelle Lahair; Richard A Ferland; Linda S Steelman
Journal:  Adv Enzyme Regul       Date:  2009-11-04

5.  p110α Hot Spot Mutations E545K and H1047R Exert Metabolic Reprogramming Independently of p110α Kinase Activity.

Authors:  Aditi Chaudhari; Daniel Krumlinde; Annika Lundqvist; Levent M Akyürek; Sashidhar Bandaru; Kristina Skålén; Marcus Ståhlman; Jan Borén; Yvonne Wettergren; Katarina Ejeskär; Victoria Rotter Sopasakis
Journal:  Mol Cell Biol       Date:  2015-07-13       Impact factor: 4.272

6.  PIK3CA Somatic Mutation Status in Relation to Patient and Tumor Factors in Racial/Ethnic Minorities with Colorectal Cancer.

Authors:  Amanda I Phipps; Dennis J Ahnen; Iona Cheng; Polly A Newcomb; Aung Ko Win; Terrilea Burnett
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-05-20       Impact factor: 4.254

Review 7.  Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.

Authors:  Ebubekir Dirican; Mustafa Akkiprik; Ayşe Özer
Journal:  Tumour Biol       Date:  2016-02-26

8.  Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy.

Authors:  Stephen L Abrams; Linda S Steelman; John G Shelton; William Chappell; Jörg Bäsecke; Franca Stivala; Marco Donia; Ferdinando Nicoletti; Massimo Libra; Alberto M Martelli; James A McCubrey
Journal:  Cell Cycle       Date:  2010-05-15       Impact factor: 4.534

9.  Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas.

Authors:  Maurits de Vries; Inge Briaire-de Bruijn; Anne-Marie Cleton-Jansen; Martijn J A Malessy; Andel G L van der Mey; Pancras C W Hogendoorn
Journal:  Virchows Arch       Date:  2012-12-08       Impact factor: 4.064

10.  E17K substitution in AKT1 in prostate cancer.

Authors:  J L Boormans; H Korsten; A C J Ziel-van der Made; G J L H van Leenders; P C M S Verhagen; J Trapman
Journal:  Br J Cancer       Date:  2010-04-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.